知镜 Cognispect · 医学文献与研究工作台

Clinical Characteristics and Delays in the Care Pathway of Patients With Lung Cancer Treated at a Public Hospital in Costa Rica, 2015-2020.

Alvarado-Prado R, Ortiz-Barboza A, Blanco-Saborío A, Arguello-Méndez JC, Zavaleta-Monestel E.
Cureus · 2026-09-15 · PMID 42890300

文献摘要

Introduction Delays in the lung cancer care pathway and limited access to molecular biomarkers, targeted therapies, and immunotherapy may affect diagnosis, treatment opportunities, and survival. This study described the clinical profile, care pathway delays, biomarker testing, treatment access, and survival of patients with primary lung cancer treated at a public hospital in Costa Rica. Methods We conducted a retrospective observational study based on medical record review. Adult patients with a pathological diagnosis of primary lung cancer treated at a public tertiary-level hospital in Costa Rica between 2015 and 2020 were included (n=223). Clinical, sociodemographic, and care process variables were analyzed, including symptoms at the time of consultation, smoking history, diagnostic and therapeutic time intervals, molecular biomarker testing, treatments received, and survival from the first care episode related to suspected lung cancer until death or the end of follow-up. Results The most frequent symptoms before diagnosis were cough (n=126; 56.50%), dyspnea (n=110; 49.33%), and weight loss (n=98; 43.95%). The median time between documented suspicion and pathological diagnosis was 34 days (IQR: 21-73; n=213), although extreme values exceeding 1000 days were observed. Molecular biomarker testing was recorded in 106 patients (47.53%), and targeted therapy or immunotherapy was documented in 45 patients (30.00%). Among patients who received targeted therapy or immunotherapy, 29 (64.44%) accessed these treatments through administrative requests to higher institutional authorities outside the standard care protocol. The estimated five-year survival from the first care episode related to suspected lung cancer was 1.9% (95% CI: 0.5-5.1). Conclusions This cohort showed frequent diagnostic delays, high variability in care pathway intervals, limited access to molecular biomarkers and innovative therapies, and low five-year survival from the first care episode related to suspected lung cancer. These findings support the need to strengthen suspicion, referral, timely diagnosis, and equitable access to diagnostic technologies and therapeutic alternatives for patients with lung cancer.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。